40+ Presentations from Top Biopharma in 2022
Producing Challenging Protein Targets for Drug Discovery
Bryony Ackroyd, PhD, Senior Protein Scientist, Discovery Biology & Discovery Sciences R&D, AstraZeneca
Direct Tie2 Agonists Promote Vascular Stability for the Intravitreal Treatment of Diabetic Macular Edema
Nicholas Agard, PhD, Principal Scientist, Antibody Engineering, Genentech, Inc.
Exploring in silico Approaches for Antibody Drug Conjugates Developability Assessments
Marc Bailly, PhD, Principal Scientist, MSD
Highly Concentrated SubQ Formulations and Tackling Protein Aggregation
Karoline B. Bechtold-Peters, PhD, Senior Strategy & Technology Leader, Pharmaceuticals & Biopharma Process, Novartis Pharma AG
Long-Term Stability Predictions of Therapeutic Proteins in Solution from Short-Term Stability Data
Matjaz Boncina, PhD, Scientist, Biologics Drug Product, Technical Research and Development, Global Drug Development, Novartis
Analytical Ultracentrifugation as a Multi-Attribute Release and Characterization Method for AAV-Based Products
George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen
Optimization of Antibody Discovery from Multiomic Single-Cell B Cell Dataset
Adrian Carr, PhD, Data Science Team Leader Kymab, Sanofi
Overcoming Safety and Efficacy Challenges of Dual Checkpoint Inhibitor Combinations
Jonathan D. Cheng, Senior Vice President & Therapeutic Area Head, Oncology Clinical Development, Bristol Myers Squibb Co.
Accelerating Drug Discovery: A Refresh of the Lead Panel Generation Phase within Biopharm Discovery
Edward Coulstock, PhD, Associate Fellow & Scientific Leader, BMPD MDE, GlaxoSmithKline
The Polysorbate Challenges in Biotherapeutic Formulations – Digging into the Mechanism of Metal-Catalyzed Oxidation of PS80 & mAb to Develop Mitigations
Camille Dagallier, PhD, Senior Formulation Scientist, Biologics Drug Product Development & Manufacturing, Sanofi R&D
Combining Mammalian Libraries and Microfluidics for Versatile Antibody Hit Discovery and Optimization
Achim Doerner, PhD, Principal Scientist, Protein Engineering & Antibody Technologies, Merck Healthcare KGaA
AAV and mRNA Delivery of VHH Intrabodies for in vivo Targeting of Intracellular Proteins
Erwin De Genst, PhD, Senior Research Scientist, AstraZeneca
Biophysical and Functional Characterisation of IgG1 Antibodies with Engineered Hexamerization Propensity
Simone De Haij, PhD, Director Functional Characterization & Bioassays, Genmab BV
Immunotherapy of Cancer in the Adjuvant Setting
Nageatte Ibrahim, MD, VP, Oncology & Global Clinical Development, MSD
In silico Approaches towards Developability Assessment and Optimization of NBEs
Andreas Evers, PhD, Principal Scientist, Computational Chemistry & Biology, Global Research & Development Discovery Technology, Merck Healthcare KGaA
Development Considerations of New Modalities
Achim Frauenschuh, Group Head, Late Stage Purification Process Development, Novartis Pharma AG
Harmonised MAM Platform across Sanofi CMC Development Sites for Process Support and Characterization
Yann Fromentin, Team Manager, High Throughput Analysis & Biopharmaceutical Development, Sanofi
From Data to Predictions: Virtual Screening for Multi-Specific Protein Therapeutics
Norbert Furtmann, PhD, Head, Computational & High-Throughput Protein Engineering, Large Molecule Research, Sanofi
Identifying and Validating Novel Oncology ADC Targets
Mark J. Austin, PhD, Team Leader, Display Technology, CRUK AstraZeneca Antibody Alliance Laboratory
Developability Profiling in Lead Discovery: Keeping the Funnel Wider for Longer
Emma R. Harding, PhD, Director & Head, Molecular Design & Engineering, GlaxoSmithKline
A Cell-based Receptor Discovery Platform Enables the Identification of Host Factors Specifically Targeted by the SARS CoV-2 Spike
Bushra Husain, PhD, Lab Head, Biologics, Bayer Pharma AG
Rapid and QC-Friendly Multi-Attribute Monitoring of Therapeutic Proteins
Somar Khalil, PhD, Scientist, Analytical Development Sciences for Biologicals, UCB
The Emerging Use of Kinase Inhibitors for the Mitigation of T Cell Bispecific (TCB) Antibody-Induced Cytokine Release
Gabrielle Leclercq, PhD, Postdoctoral Scientist, Pharma Research & Early Development, Roche
Development of New Methods for Characterization of Antibody Self-Association and Non-Specificity
Nikolai Lorenzen, PhD, Principal Scientist, Biophysics and Injectable Formulation, Novo Nordisk AS
Nanobody®-Based T Cell Engagers
Paolo Meoni, PhD, Distinguished Scientist & Project Head, Sanofi
Application of Scaled-Down Models to Accelerate the Process Development of a Highly Potent Neurotoxin Using a Modified E. coli
Williams Olughu, PhD, Principal Scientist, Ipsen
Multiplex Digital PCR, an Analytical Method for Gene Therapy, Delivering a Broad Versatile and Meaningful Readout
Robert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, Takeda
3D-DLS: An Optical Microrheological Alternative to Traditional Capillary Rheometry for Viscosity Measurements of High-Concentration Biologics
Joy Puthawala, Principal Research Associate, Sanofi
Towards ML-Based Multi-Specific Antibody Optimization
Katrin Reichel, PhD, Senior Data Scientist, Computational & HT Protein Engineering, R&D Biologics Research/Protein Therapeutics, Sanofi
Generation of Superior Host Cell Lines for Biomanufacturing Using Plasmid Design & Cell Line Engineering Technologies
Anett Ritter, PhD, Investigator III, Cell Line Screening & Development, Novartis Pharma AG
Suitability of Transiently Expressed Antibodies for Clinical Studies
Sara Rodriguez Conde, PhD, Associate Director, Cell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca
CD19-Targeted Affinity-Reduced CD28-Bispecific Antibody Enhances and Prolongs Anti-Tumor Activity of Glofitamab
Johannes Sam, PhD, Principal Scientist & Group Leader, Roche Innovation Center Zurich
Impact of Conjugation Site Selection & Method on the Stability and PK of ADCs
Christian A. Schroeter, PhD, Associate Director, ADCs & Targeted NBE Therapeutics, Merck KGaA
Understanding Protein-Protein Interaction in Protein Coformulation Drug Product
Jing Song, Associate Principal Scientist, Materials and Biophysical Characterization, AR&D, MSD
Discovery and Characterisation of the CD96 Antibody GSK6097608, a High-Affinity, Antagonistic Anti-CD96 Antibody for Cancer Immunotherapy
Sarah Stuart, PhD, Team Leader, Biopharm Discovery, GlaxoSmithKline
Enhancing Endogenous and Synthetic Immunity with Engineered Antibody-Fusion Proteins for Cancer Immunotherapy
Pablo Umaña, PhD, Head, Cancer Immunotherapy Discovery, Roche
New Technologies for High-Throughput Screening of Membrane Protein Targets
Erik Vernet, PhD, Director, Antibody Technology, Novo Nordisk
Discovery of Antibodies against a Complex Target
Trevor Wattam, PhD, Scientific Leader, Antibody Discovery, GlaxoSmithKline
Building Analytical Platform to Enable Efficient Drug Development
Bernice Yeung, PhD, Head of Analytical Development (Chemistry), Biogen
Development of Potent Antagonist Against Target-of-Interest with Phage-Displayed Alternative Scaffolds
Yingnan Zhang, PhD, Senior Scientific Manager, Early Discovery Biochemistry, Genentech, Inc.
Generation and Engineering of Mono- and Bispecific Cattle-Derived Ultralong CDR-H3 Antibodies by Yeast Surface Display
Stefan Zielonka, PhD, Protein Engineering & Antibody Technologies, Merck KGaA